In almost all disease processes in biological systems, changes in protein phosphorylation have an inherent cause-and-effect in onset, progression and decline. K-Scan®’s ability to reveal the phosphoproteomic signatures of network circuitry gives powerful insights in many therapeutic areas.
Peripheral Blood (PBMC)
Kinomica’s services in Oncology drug development deliver identification of targets, mode of action studies, off-target effects, drug resistance mechanisms and improved patient stratification for Clinical Trials.
Talk to our Experts
To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.
If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.
“Our technology can look at over 10,000 proteins in one simple experiment and tell researchers exactly which proteins are activated and deactivated. This is hugely important and relevant for personalised medicine“
Jane Theaker, Kinomica CEO